Compare Comfort Systems USA Inc (FIX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comfort Systems USA Inc vs TG Therapeutics Inc — how do they compare? Comfort Systems USA Inc trades at $1,683.8 (market cap $61.14B), while TG Therapeutics Inc trades at $54.82 (market cap $8.64B). The key difference: Comfort Systems USA Inc is far larger — about 7.1× TG Therapeutics Inc's market cap, and Comfort Systems USA Inc pays a 0.15% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| FIX | TGTX | |
|---|---|---|
Market Cap | $61.14B | $8.64B |
Sector | Technology | Health |
52-Week High | $2.07K | $59.06 |
52-Week Low | $532.14 | $26.39 |
Enterprise Value | $60.42B | $8.88B |
Dividend Yield | 0.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comfort Systems USA (FIX) trades at $1,655.80, down 6.72% over the past day, amid a bearish technical signal. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $10.51 versus $6.81 expected, and revenue growth projected from $9.10B in 2025 to $10.10B in 2026. Analyst consensus remains bullish with a $2,100 price target, supported by robust cash flow and a 53.29% ROE.
Outlook is positive due to AI infrastructure demand and record backlog, though high valuation multiples (P/E 50.14) and execution risks from rapid growth pose challenges. The stock offers growth potential but requires monitoring of margin sustainability and competitive pressures in the contracting services sector.
TG Therapeutics (TGTX) trades at $55.19, up 0.55% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 65.95% net income margin and 112.6% ROE, though recent quarterly EPS has missed expectations. Positive clinical trial news for Briumvi in multiple sclerosis and schizophrenia is driving investor optimism and media coverage.
The outlook is supported by robust revenue growth and pipeline expansion, but risks include clinical trial execution and recent earnings volatility. Analysts are predominantly bullish with an 84.6% buy rating, though the consensus price target of $48.50 sits below the current price, suggesting potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
